Navigation Links
Boston Scientific's Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
Date:10/22/2007

ts in September 2005, and it is currently the market- leading drug-eluting stent outside the United States excluding Japan (the TAXUS Liberte stent is not available for sale in Japan). The Company received CE Mark for the TAXUS Liberte Long Stent in May 2007. The TAXUS Liberte Stent and the TAXUS Express 2.25 mm Stent are currently pending approval by the U.S. Food and Drug Administration and are limited by federal law to investigational use and not available for sale in the United States. The Company plans to launch the TAXUS Liberte Stent in the United States in 2008.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: http://www.bostonscientific.com.

Cautionary Statement Regarding Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words. These forward- looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding clinical trials, product performance and competitive offerings. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results
'/>"/>

SOURCE Boston Scientific Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Boston Scientific Announces Schedule for EuroPcr 2007
2. Boston Life Sciences, Inc. Announces Presentation of Cethrin Phase I/IIa 6-Month Results at 75th Annual Meeting of the American Association of Neurological Surgeons
3. Kosan Presents Preclinical Antitumor and Safety Data On Next-Generation Epothilone KOS-1803 at AACR
4. New Data from Multiple Studies Show Galvus Delivers Consistent and Robust Blood Sugar Control in Patients with Type 2 Diabetes
5. To Stent or Not: Is That the Question?
6. New Study Suggests Better Patient Outcomes with CYPHER Sirolimus-Eluting Coronary Stent than with Taxus Stent in Real-World Clinical Settings
7. Positive Results for Second-Generation Taxus Liberte Coronary Stent System Highlighted in Journal of American College of Cardiology
8. Efficacy of OrbusNeichs Genous Bio-Engineered R Stent Compares Favorably to Drug-Eluting Stents
9. Abbott Announces Positive Nine-Month Results From the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
10. Abbott Announces Continued Positive Results with Xience V Everolimus Eluting Coronary Stent in Spirit Clinical Trials
11. Investigators Report COSTAR II Pivotal Drug-Eluting Stent Trial Results at EuroPCR 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
(Date:1/15/2014)... 15, 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ... CGM System as a non-invasive, wireless continuous glucose monitoring ... Executive Chairman and Interim CEO of Echo Therapeutics, will ... Equity Conference. Mr. Doman will make ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Intellectual Property Insurance for Medical-related Products and Services 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3
... Hill-Rom Holdings, Inc. (NYSE: HRC ) will release ... 2011.  The company will host a webcast the following morning ... Earnings Release:   Hill-Rom,s Fiscal 2011 Third Quarter ... be issued to the public after the close of the ...
... 2011 U.S. Senators Jerry Moran ... established the first-ever Senate Community Pharmacy Caucus, an effort ... (NCPA). (Logo: http://photos.prnewswire.com/prnh/20100106/DC33253LOGO) The ... pharmacy issues while serving as a clearinghouse of ideas ...
Cached Medicine Technology:Hill-Rom Holdings, Inc. Hosts Fiscal 2011 Third Quarter Earnings Webcast 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 2NCPA Applauds Formation of Senate Community Pharmacy Caucus by Senators Jerry Moran and Jon Tester 3
(Date:4/16/2014)... , While it is well known that fertility treatments ... and that multiples are at elevated risk of premature ... in Fertility and Sterility . The ... can reduce the odds of multiple births and prematurity, ...
(Date:4/15/2014)... decades-old medical mystery and in the process have found a ... about 1.5 million people a year. The researchers say they now ... has been in use for more than 50 years even ... is to the microbes it attacks. , A report ...
(Date:4/14/2014)... advances have been made in chemotherapy over the past ... healthy tissues continues to be a major challenge. ... delivery, including the use of nanocarriers, or capsules, that ... in the body. , The catch? These carriers are ...
(Date:4/14/2014)... American Associations for Dental Research (IADR/AADR) have published a ... and Craniofacial Manifestations." The complete review by researchers Sunday ... Collins, Brian L. Foster, Rachel I. Gafni, Janice S. ... Timothy Wright is published in the OnlineFirst portion of ...
(Date:4/14/2014)... treatment decisions leaves cancer patients feeling more satisfied with ... the experience, researchers from the Perelman School of ... the journal Cancer . , In a study ... MD , an associate professor in the department in ...
Breaking Medicine News(10 mins):Health News:Preterm births, multiples, and fertility treatment 2Health News:Preterm births, multiples, and fertility treatment 3Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 2Health News:Potent, puzzling and (now less) toxic: Team discovers how antifungal drug works 3Health News:Nano shake-up 2Health News:Rare bone diseases and their dental, oral and craniofacial manifestations 2Health News:Shared decision making during radiation therapy improves patient satisfaction 2Health News:Shared decision making during radiation therapy improves patient satisfaction 3
... with CyberKnife Radiosurgery Worldwide, SUNNYVALE, Calif., Nov. ... global leader in the field of radiosurgery,today announced ... to treat more than 4,000 lung cancer patients ... patients in total have been treated,with CyberKnife radiosurgery ...
... 25% of all,cancers are due to genetic factors, patients that ... on the lookout for the early warning signs of,cancer. This ... from,both a medical and psychological prospective. Cancer does run ... Today, suggests it is misleading to think of cancer as ...
... (NYSE: SGP ) today announced that it ... Commission (FTC) regarding its,planned acquisition of Organon BioSciences ... 2007. Organon BioSciences is comprised mainly of ... health business. It also,includes Nobilon, the human vaccine ...
... of Georgia Drug Agency Approves Protocol for New Clinical ... of Bavituximab in Combination with ... Inc. (Nasdaq: PPHM ), a clinical stage biopharmaceutical,company ... C virus (HCV) infection, today announced that its Phase ...
... following is being,issued by the National Council on Disability:, ... to December 1, 2007., WHERE:, Hyatt Regency Boston ... November 29, 2007, 8:30 a.m. - 10:00 a.m. ... Vaughn -- Introduction of Council Members, NCD staff and ...
... 16 21st Services has created its,first Medical Advisory ... an innovative approach in the life settlement industry. ... the sophistication,of its underwriting model and its life expectancy ... up of physicians from,across the country who are experts ...
Cached Medicine News:Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 2Health News:Accuray Exceeds 4,000 Lung Cancer Patients Treated with CyberKnife(R) System 3Health News:Genetics and Risk, This Week on Your Cancer Today(TM) 2Health News:Schering-Plough Receives Clearance From U.S. Federal Trade Commission for Planned Acquisition of Organon Biosciences N.V. 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 2Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 3Health News:Peregrine Pharmaceuticals Receives Approval to Begin New Phase II Trial of Bavituximab in Patients With Metastatic Breast Cancer 4Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 2Health News:National Council on Disability (NCD) Hosts Quarterly Meeting 3Health News:In Progressive Move, 21st Services Forms Independent Medical Advisory Board to Study Longevity, Mortality Risk 2
De Soutter supply clean cast removal saws that are low in voltage and contain an integrated extractor system, combining state-of-the-art ergonomics with performance and durability....
The three point staple, used for valgus tibial osteotomy, is easy and quick to fit, with a compact size compared with other existing systems....
... the osteotomy staples is quite similar to the type ... inner position of the anti recoil contours and the ... There are 3 kinds of staples: 1. Straight ... staples can have 3 different widths: 20mm, 26 mm ...
A new generation of ORTHOMED S.A. fixation staples, manufactured from cobalt-chromium alloy: tried and test strength and tolerance...
Medicine Products: